Home › Funds › Contrarius Group Holdings Ltd › NTLA

Contrarius Group Holdings Ltd position in NTLA

INTELLIA THERAPEUTICS INC · Health Care

Contrarius Group Holdings Ltd reported holding 2,432,219 shares of NTLA (INTELLIA THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$29.3M, representing 1.43% of its reported portfolio and ranking #15 among its reported holdings. Contrarius Group Holdings Ltd has disclosed NTLA holdings in 8 of the last 8 reported quarters, going back to Q4 2024.

Latest position (Q3 2026)2.43M sh
Reported value held$29.33M
Portfolio Weight1.43%
First reportedQ4 2024
Last changeAdd
Updated2026-11-10

Last updated: 2026-11-10 · Source: SEC EDGAR Form 13F-HR

How Contrarius Group Holdings Ltd's NTLA position evolved

Contrarius Group Holdings Ltd first disclosed a stake in NTLA in Q4 2024 at 1,011,863 shares (US$11.8M). The position peaked in Q3 2025 at 5,889,936 shares, worth US$101.7M. Across 8 filings, Contrarius Group Holdings Ltd increased the stake 5 time(s), trimmed it 2 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 2,432,219 shares valued at US$29.3M — an increase of 476,991 shares quarter over quarter.. Notable position changes include a 100% increase in Q1 2025 (shares rose 32% over the following quarter), a 279% increase in Q3 2025 (shares fell 48% over the following quarter), a 168% increase in Q1 2026 (shares rose 32% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2024 1.01M $11.80M New
Q1 2025 2.02M $14.37M Add
Q2 2025 1.55M $14.56M Reduce
Q3 2025 5.89M $101.72M Add
Q4 2025 714.48K $6.42M Reduce
Q1 2026 1.91M $24.51M Add
Q2 2026 1.96M $33.08M Add
Q3 2026 2.43M $29.33M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About NTLA and 13F data

NTLA (INTELLIA THERAPEUTICS INC) is a Health Care company. 38 other funds we track also report a position in NTLA — the largest reported positions include ARK Invest (US$285.5M), RA CAPITAL MANAGEMENT, L.P. (US$76.6M), Amova Asset Management Americas, Inc. (US$49.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding NTLA

All NTLA fund holders →

FAQ

How long has Contrarius Group Holdings Ltd held NTLA?

Contrarius Group Holdings Ltd has disclosed NTLA holdings in 8 of the last 8 reported quarters, going back to Q4 2024.

What is Contrarius Group Holdings Ltd's current position in NTLA?

As of Q3 2026, Contrarius Group Holdings Ltd holds 2.43M shares of NTLA (INTELLIA THERAPEUTICS INC), valued at $29.33M, representing 1.43% of its reported portfolio and ranking #15.

Has Contrarius Group Holdings Ltd been buying or selling NTLA?

In the latest 13F filing (Q3 2026), Contrarius Group Holdings Ltd increased its position in NTLA. The position peaked in Q3 2025 at 5.89M shares.

Which other funds hold NTLA?

Other major institutional holders of NTLA include ARK Invest, RA CAPITAL MANAGEMENT, L.P., Amova Asset Management Americas, Inc., among 38 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.